Systematic Review on Treatment Trials of Tocilizumab: A Repurposing Drug against COVID-19

Author:

Banerjee Shilpita1,Mahapatra Ajit Kumar1

Affiliation:

1. Department of Chemistry, Indian Institute of Engineering Science and Technology Shibpur, Howrah, 711103,India

Abstract

Background: Coronavirus disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a global issue today. There exists an ongoing health crisis all over the world, and efficacious drugs against COVID-19 are not available yet. Therefore, on an urgent basis, scientists are looking for safe and efficacious drugs against SARSCoV- 2. Methods: The reported individual patient data and clinical outcomes, including the rate of recovery and mortality, patients’ characteristics, and complications, are reviewed. Randomized controlled trials, single-center cohort studies, and different case studies are provided, and the PICO model is used to illustrate the outcomes. Results: There exist several FDA (U.S Food and Drug Administration) approved anti coronavirus drugs that sometimes are unsuccessful in curing COVID-19 critical conditions. It has been observed that a humanized monoclonal antibody, Tocilizumab (licensed for the treatment of rheumatoid arthritis), targeting the interleukin-6 (IL-6) receptor, has an integral role in the treatment of COVID-19. Conclusion: The cause behind the mortality of COVID-19 patients was found to be the Cytokine Release Syndrome (CRS). Therefore, besides other antiviral drugs, the utilization of tocilizumab should also be considered as it can effectively block IL-6 and reduce the inflammatory signal.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3